Edward L. Erickson
President and CEO, BioNanomatrix
Edward L. Erickson has over 25 years of experience in the management, leadership and oversight of life science-based companies. His expertise spans research products, diagnostics, and therapeutics and he has served as president, CEO or a director of over a dozen companies in these fields, three of which successfully completed IPOs under his leadership. He has raised a total of approximately $500,000,000 in equity and debt capital in both the private and public capital markets and he has considerable merger and acquisition experience. Mr. Erickson holds a BS with distinction in Mathematics with a minor in Physics and an MS in Mathematics from the Illinois Institute of Technology. He received an MBA with high distinction from Harvard University where he was elected a Baker Scholar and was awarded the Loeb Rhodes Fellowship in Finance.
Tracy Warren
Chairman
Tracy Warren is a general partner of Battelle Ventures, a $220-million fund based in Princeton, N.J., and of its Knoxville, Tenn.-based, $35-million affiliate fund, Innovation Valley Partners, for which she focuses on investments in health & life sciences and emerging energy technologies.
Ms Warren’s other life-science activities include being acting CEO of regenerative-medicine company NellOne Therapeutics, a board director of cardiovascular-device company Endovalve and a board observer of CNS-specialty-pharmaceutical company NuPathe. She also is a member of the Ben Franklin Technology Partners biotechnology and life sciences investment advisory committee.
Ms Warren started in venture capital in 2001 after being an analyst and associate in SG Cowen (now Cowen and Company) Securities & Health Care Mergers and Acquisitions and Corporate Finance divisions. She holds a B.S. degree from New York University Stern School of Business and an MBA from Columbia Business School.